Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 50Pancreatic Neoplasms 33Prostatic Neoplasms 31Brain Neoplasms 28Lung Neoplasms 26Neoplasm Metastasis 24Melanoma 21Carcinoma, Hepatocellular 20Breast Neoplasms 17Carcinoma, Renal Cell 12Colorectal Neoplasms 11Squamous Cell Carcinoma of Head and Neck 10Neoplasms 9Small Cell Lung Carcinoma 7Urinary Bladder Neoplasms 5Recurrence 5Head and Neck Neoplasms 5Glioblastoma 5Adenocarcinoma of Lung 5Sarcoma 4Liver Neoplasms 4Kidney Neoplasms 4Uterine Cervical Neoplasms 3NSCLC 3Clear-cell metastatic renal cell carcinoma 3Cholangiocarcinoma 3Uveal Melanoma 2Unresectable Locally Recurrent Rectal Cancer 2Triple Negative Breast Neoplasms 2Rectal Neoplasms 2

Interventions

palbociclib 1Urinary Diversion 1Radiosurgery 1Mitomycin 1Immune Checkpoint Inhibitors 1Gels 1Cystectomy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Urologic Diseases × Radiosurgery × Clear all
NCT05241340 2025-10-24

RAD-VACCINE

The Methodist Hospital Research Institute

Phase 2 Active not recruiting
33 enrolled
Genitourinary

Urinary Bladder Diseases, Urinary Bladder Neoplasms, Urologic Diseases, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡